AC Immune says partner J&J pauses enrollment in mid-stage trial for Alzheimer's drug
Source: SeekingAlpha
2026-02-18 06:58:41 ET
More on AC Immune, Johnson & Johnson
- Johnson & Johnson: Fraud Claim Dismissal Today Is Not A Sign Talc Litigation Is Over
- Johnson & Johnson: Strong Momentum Heading Into 2026
- Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript
- J&J gains monthly dosing approval for Rybrevant Faspro
- J&J hit with $250K jury verdict in Philadelphia talc powder case
Read the full article on Seeking Alpha
For further details see:
AC Immune says partner J&J pauses enrollment in mid-stage trial for Alzheimer’s drug
AC Immune SA
NASDAQ: ACIU
ACIU Trading
-2.51% G/L:
$2.965 Last:
192,538 Volume:
$3.02 Open:
ACIU Latest News
March 05, 2026 07:00:00 am
AC Immune Announces Upcoming Industry Symposium on Parkinson's Disease and Presentation at AD/PD(TM) 2026
December 11, 2025 07:00:00 am
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease
November 11, 2025 07:00:00 am
AC Immune to Present at the Jefferies 2025 London Healthcare Conference
ACIU Stock Data
$309,766,013
46,088,363
N/A
39
N/A
Biotechnology & Life Sciences
Healthcare
CH
Lausanne
